Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

T Cell Activation and Clonal Selection

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

B Cell Activation and Differentiation

B Cell Activation and Differentiation

The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...

Antigen Presenting Cells

Antigen Presenting Cells

The immune system is a complex network of cells and molecules that protects the body from foreign invaders. T cells, a type of white blood cell, play a crucial role in this process. They recognize and attack foreign substances, such as pathogens, that enter the body.
T cells require the help of antigen-presenting cells (APCs), which process foreign antigens into smaller fragments that can be recognized by T cells. These APCs are highly specialized cells that efficiently internalize antigens...

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

Cell-mediated Immune Responses

Cell-mediated Immune Responses

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Allogeneic Hematopoietic Cell Transplant Following Standard of Care Brexucabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia: Results from the Real-World Outcomes Collaborative of Chimeric Antigen Receptor T in Adult Acute Lymphoblastic Leukemia.

Transplantation and cellular therapy·2026

Same author

Consensus Recommendations for CAR T-Cell Administration in Adult Acute Lymphoblastic Leukemia: a Modified Delphi Study.

Blood·2026

Same author

Prioritized health outcomes for adolescents and young adults with acute lymphoblastic leukemia.

Blood neoplasia·2026

Same author

American Society of Hematology 2026 guidelines for management of relapsed/refractory acute lymphoblastic leukemia in adolescents and young adults.

Blood advances·2026

Same author

Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL.

Blood·2026

Same author

Immune targeting in Ph-negative and Ph-positive B-ALL: improving outcomes and minimizing chemotherapy in adult B-ALL.

Hematology. American Society of Hematology. Education Program·2025

Search research articles

Related Experiment Video

Updated: Aug 18, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Optimal approach to T-cell ALL.

Kristen M O'Dwyer¹

¹Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY.

Hematology. American Society of Hematology. Education Program

|December 9, 2022

Summary

Most childhood T-lineage acute lymphoblastic leukemia (T-ALL) is curable with chemotherapy. Relapsed T-ALL in adults remains largely incurable, driving research into novel immunotherapies and targeted agents.

Area of Science:

Hematology
Oncology
Immunology

Background:

T-lineage acute lymphoblastic leukemia (T-ALL) presents a significant challenge in adult oncology, with high relapse rates.
Current salvage chemotherapy for relapsed T-ALL demonstrates limited efficacy, necessitating novel therapeutic approaches.

Approach:

Review of contemporary frontline chemotherapy regimens for adult T-ALL.
Summary of emerging targeted and immune therapeutics in early-phase clinical trials for relapsed T-ALL.
Analysis of minimal residual disease (MRD) assessment in optimizing frontline treatment strategies.

Key Points:

Frontline chemotherapy optimization and MRD-guided treatment intensification have improved survival in pediatric and young adult T-ALL.
Relapsed T-ALL in adults is often incurable with existing salvage regimens.

More Related Videos

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Related Experiment Videos

Last Updated: Aug 18, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Novel immunotherapies and small-molecule inhibitors show promise for relapsed T-ALL.

Conclusions:

Intensive frontline therapy remains crucial for achieving cure in T-ALL until effective salvage strategies are established.
Ongoing clinical trials are exploring innovative treatments for relapsed T-ALL.
Defining optimal treatment approaches requires integrating novel therapeutics with established chemotherapy.